Which P2Y12 inhibitors are appropriate choices in NSTEMI?

Which P2Y12 inhibitors are appropriate choices in NSTEMI?

• A. Clopidogrel or Ticagrelor
• B. Prasugrel only
• C. Abciximab
• D. Aspirin

Answer: (A)

In NSTEMI, dual antiplatelet therapy is used, combining aspirin with a P2Y12 inhibitor to prevent further platelet activation and thrombus formation. The P2Y12 inhibitors available include clopidogrel, prasugrel, and ticagrelor. Abciximab is a GP IIb/IIIa inhibitor, not a P2Y12 blocker, and aspirin is not a P2Y12 inhibitor. Among the given options, clopidogrel and ticagrelor are the P2Y12 inhibitors, making that choice the correct one. The option mentioning prasugrel only is incomplete because prasugrel is also a P2Y12 inhibitor and can be used depending on patient factors.

In NSTEMI, dual antiplatelet therapy is used, combining aspirin with a P2Y12 inhibitor to prevent further platelet activation and thrombus formation. The P2Y12 inhibitors available include clopidogrel, prasugrel, and ticagrelor. Abciximab is a GP IIb/IIIa inhibitor, not a P2Y12 blocker, and aspirin is not a P2Y12 inhibitor. Among the given options, clopidogrel and ticagrelor are the P2Y12 inhibitors, making that choice the correct one. The option mentioning prasugrel only is incomplete because prasugrel is also a P2Y12 inhibitor and can be used depending on patient factors.